期刊文献+

类风湿关节炎患者血清和滑膜骨桥蛋白的测定 被引量:2

The change of serum osteopontin concentration and synovial membrane expression of osteopontin in patients with rheumatoid arthritis
原文传递
导出
摘要 目的研究骨桥蛋白(OPN)在类风湿关节炎(RA)患者外周血中的浓度变化及在滑膜的表达,探讨OPN在RA患者中的发病机制。方法收集91例RA患者以及29名正常对照人群临床资料和血清,用酶联免疫吸附试验(ELISA)方法检测OPN在RA患者外周血中的浓度,分析其变化和RA临床及实验室指标的关系。收集7例RA患者和1名正常对照的滑膜组织,用免疫组织化学的方法观察OPN的表达情况。结果与正常对照组相比,活动组和非活动组的RA患者外周血中OPN水平均明显升高(P〈0.01),且与RA患者的部分临床指标有相关性:与压痛关节数(r=0.435,P=0.005)、关节的X线分期(r=0.415,P=0.007)、关节功能(r=0.394,P=0.012)显著相关。OPN在RA滑膜组织大量表达,而在正常对照仅见OPN的少量表达。结论OPN在RA患者外周血中浓度显著升高,且在滑膜表达明显,OPN可能与RA滑膜增生、骨侵蚀有关。 Objective To explore the change of serum osteopontin concentration and the expression of OPN in the synovial membrane of patients with rheumatoid arthritis. Methods We measured the serum osteo- pontin concentration in 91 RA patients and 29 sex-and age-matched normal control subjects using an enzyme-linked immunoabsorbent assay and collected clinic data at the same time. The expression of OPN in the synovial membrane from 7 RA patients and 1 patient with trauma was examined by immunohistochemistry. Results Serum osteopontin concentrations were significantly higher in both active and inactive RA patients than that in the normal control group: (65±22) ng/ml in active RA, (56±22) ng/ml in inactive RA patients and (26±8) ng/ml (P〈0.005) in normal controls. Increase in OPN concentration correlated positively and sig- nificantly with the number of tender joints, joint x-ray change stages, and joint function(r=0.435, P=0.005, r= 0.415, P=0.007, r=0.394, PP=0.012). The expression of OPN was observed in all samples from patients. OPN was expressed in the 'synovial lining and sublining layer. Conclusion The above results suggest that the production of osteopontin is associated with joint destruction in RA.
出处 《中华风湿病学杂志》 CAS CSCD 2008年第4期238-241,I0001,共5页 Chinese Journal of Rheumatology
基金 安徽省教育厅自然科学研究基金资助项目(2006KJ073C) 合肥市科研基金资助项目(2006002)
关键词 关节炎 类风湿 骨桥蛋白 血清 滑膜 Arthritis, rheumatoid Osteopontin Serum Synovial membrane
  • 相关文献

参考文献2

二级参考文献10

  • 1Pope R M, Pahlavani M A, Lacour E et al. Antigen specificity of rheumatoid synovial fluid ymphocytes.Arthritis Rheum, 1989,32:1 371-1 380.
  • 2Rankin E C, Choy E H, Kassimos D et al. The therapeutic effects of an engineered hman anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol,1995, 34:334-342.
  • 3Ashkar S, Weber G F, Panoutsakopoulou V et al.Eta- 1 (Osteopontin): An early component of type- 1 (cell-mediated) immunity. Science, 2000, 287:860-864.
  • 4Chabas D, Baranzini S E, Mitchell D et al. The influence of the proinflammatory cytokine,osteopontin, on autoimmune demyelinating disease. Science, 2001,294:1 731-1 735.
  • 5Petrow P K, Hummel K M, Schedel J et al.Expression ofosteopontin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum,2000, 43:1 597-1 605.
  • 6Shanahan J C, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumaticdisease. Clin. Immunol, 2002, 103:231-242.
  • 7KAPLAN D, FELDMAN J. A preliminary study of excess risk of cardiovascular disease in the mothers of patients with rheumatoid arthritis[J]. Am J Epidemiol, 1991, 133:715-720.
  • 8BURGER P C, WAGNER D D. Platelet P-selectin facilitates atherosclerotic lesion development[J]. Blood,2003, 101:2661-2666.
  • 9RIDKER P M, BURING J E, RIFAI N. Soluble P selectin and the risk of future cardiovascular events[J]. Circulation, 2001, 103:491-495.
  • 10BLANN A D, NADAR S K, LIP G Y, et al. The adhesion molecule P-selectin and cardiovascular disease[J]. Eur. Heart J, 2003, 24.2166-2179.

共引文献52

同被引文献17

  • 1Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med, 2000, 11: 279-303.
  • 2Wong CK, Lit LC, Tam LS, et al. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford), 2005, 44: 602-606.
  • 3Petrow PK, Hummel KM, Schedel J, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum, 2000, 43: 1597-1605.
  • 4Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum, 2002, 46: 1094-1101.
  • 5Yumoto K, lshijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type Ⅱ collagen anti- body-induced arthritis in mice. Proc Natl Acad Sci USA, 2002, 99: 4556-4561.
  • 6O' Regan A, Berman JS. Osteopontin: a key cytokine in cell- mediated and granulomatous inflammation. Int J Exp Pathol, 2000, 81: 373-390.
  • 7Denhardt DT, Noda M, O' Regan AW, et al. Osteopontin as a to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 2001, 107: 1055-1061.
  • 8Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000, 287: 860-864.
  • 9O' Regan AW, Hayden JM, Berman JS, et al. Osteopontin augments CD3-mediated interferon-γ, and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol, 2000, 68: 495-502.
  • 10Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood, 2005,106: 946-955.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部